Growth hormone doesn’t just govern how we grew as children; in adults, it plays an ongoing role in body composition, metabolism, tissue repair, sleep, and cognitive function. Production declines steadily after thirty, and the effects add up quietly: fatigue deepens, recovery slows, and muscle gives way to fat.

The conventional response has been synthetic growth hormone (HGH), but for most patients there’s a more physiological approach: growth hormone peptide therapy, which signals the pituitary gland to release the body’s own growth hormone in natural patterns, with a more favorable side effect profile.

Below are three peptide protocols we use for growth hormone optimization at Meeting Point Health. The right choice depends on what a patient is trying to address and what their health picture reveals.

1. CJC-1295 and Ipamorelin

CJC-1295 and Ipamorelin is a well-rounded starting protocol with broad benefits and a clean side effect profile. The two work through separate but complementary mechanisms:

Together, they raise total growth hormone output more than either could alone. Both are given by subcutaneous injection, typically at night to align with the body’s natural release during deep sleep.

What to expect with CJC-1295 and Ipamorelin: Improved sleep quality (often the first change patients notice), support for lean muscle and fat reduction, and better recovery from exercise and injury as IGF-1 rises, with minimal side effects.

Who May Benefit from CJC-1295 & Ipamorelin? CJC-1295 & Ipamorelin are often recommended for individuals looking to naturally support growth hormone production and improve their overall health, recovery, and body composition. This therapy may be a good fit for those who:

  • Are experiencing a natural decline in growth hormone and IGF-1 with age.
  • Have difficulty getting sound sleep or recovering after exercise.
  • Struggle to build or maintain lean muscle mass.
  • Have noticed an increase in stubborn abdominal fat.

2. Tesamorelin

What is Tesamorelin? Tesamorelin is a stabilized GHRH analog, a longer-lasting match to the body’s natural growth-hormone-releasing signal. Because it stays active longer, it produces a more robust effect on IGF-1.

Elevated IGF-1 drives meaningful reductions in visceral fat, the deep abdominal fat tied to insulin resistance and cardiovascular risk that diet and exercise alone often can’t move. It also supports nerve repair, giving Tesamorelin a cognitive benefit the other protocols don’t have. It’s given by subcutaneous injection and prescribed based on your IGF-1 levels and metabolic picture.  

Who May Benefit from Tesamorelin? Tesamorelin is commonly recommended for those who: 

  • Carry Excess Visceral Fat: Helps target deep abdominal fat associated with metabolic and cardiovascular health risks.
  • Have Metabolic Dysfunction: Supports healthier metabolic function and overall body composition.
  • Experience Insulin Resistance: May improve insulin sensitivity and promote more efficient glucose metabolism.
  • Want to Support Cognitive Health: May help promote healthy brain function and cognitive performance as part of a comprehensive wellness plan.
  • Need Enhanced Tissue & Nerve Repair: Supports the body’s natural regenerative processes, including nerve health and recovery.
  • Require a Strong IGF-1 Response: Often recommended for patients who may benefit from a more robust increase in IGF-1 levels under medical supervision.

3. IGF1-LR3

What is IGF1-LR3? IGF1-LR3 is a modified version of the body’s natural IGF-1 that bypasses the pituitary and goes straight to tissue receptors. Its altered structure extends its activity in the body, supporting longer-lasting cellular repair, which may be well-suited for improving body composition, protecting tissue integrity, and preserving muscle even during caloric restriction or metabolic stress.

Who May Benefit from IGF1-LR3? IGF1-LR3 is typically recommended for patients who need a more advanced anabolic and regenerative approach than traditional growth hormone peptides. This therapy may be a good fit for individuals who:

  • Are Pursuing Advanced Body Recomposition: Looking to reduce body fat while supporting a lean, athletic physique.
  • Want to Preserve Lean Muscle: Helps maintain muscle mass during other metabolic changes.
  • Want To Enhance Their Tissue Recovery Levels: Ideal for those recovering from intense training, repetitive physical stress, or demanding lifestyles.
  • Have Specialized Performance or Regenerative Goals: Appropriate for patients whose treatment plans require direct, long-acting IGF-1 support under medical supervision.

How Growth Hormone Peptides Are Prescribed

Before recommending any growth hormone peptide, our providers at Meeting Point Health evaluate IGF-1 often alongside a full hormone panel, which may include sex hormones, adrenal function, and thyroid status. Optimizing growth hormone in isolation while ignoring a suppressed thyroid or dysregulated cortisol can produce incomplete results.

For patients who are also candidates for bioidentical hormone replacement therapy (BHRT), growth hormone peptides and BHRT can be used as complementary layers of the same protocol, each addressing a different piece of hormonal decline. The goal is never to chase a number, but rather understand your physiology and design a protocol that fits it.

If you’re in the greater Philadelphia area and curious whether growth hormone peptide therapy fits your goals, schedule a discovery call with Meeting Point Health to get started.

Helpful Links:

Related Reading:

Frequently Asked Questions

Are growth hormone peptides the same as synthetic HGH? No. Synthetic HGH introduces growth hormone from an outside source, bypassing the pituitary and suppressing the body’s own production over time. Growth hormone peptides work upstream, prompting the pituitary to produce its own growth hormone in natural patterns, preserving your body’s feedback mechanisms with a more favorable safety profile.

Do I need a prescription for these peptides? Yes. All growth hormone peptides at Meeting Point Health are prescribed and administered under clinical supervision, with dosing and protocol design individualized to your labs and history.

How long does it take to see results? Most patients notice better sleep within two to four weeks. Changes in body composition, energy, and recovery tend to follow over the next two to three months as IGF-1 stabilizes. Results vary by peptide, starting point, and the rest of your protocol.

Can growth hormone peptides be combined with other treatments? In most cases, yes – often alongside bioidentical hormone replacement therapy or mitochondrial peptides as part of a broader protocol, depending on your labs and clinical picture.

References
  • Badran, A. S., Helal, A., Shata, K. S., & Ayesh, H. (2026). Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity research & clinical practice, 20(1), 2–12. https://doi.org/10.1016/j.orcp.2026.01.002 
  • Engel, M. G., Narayan, S., Cui, M. H., Branch, C. A., Zhang, X., Gandy, S. E., Ehrlich, M., & Huffman, D. M. (2024). Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. Journal of Alzheimer’s Disease. https://pubmed.ncbi.nlm.nih.gov/39610283/
    PMC – NIH
  • Fredrick, J. R., Blackman, M. R., Corpas, E., Merriam, G. R., Kargi, A. Y., & Garcia, J. M. (2026). Growth Hormone and Aging. Endotext [Internet].
  • Liu, Y., Wu, D., Hua, H., Mei, S., Yan, X., Xu, X., Li, L., Wu, Y., Zhu, J., Wu, M., & Li, W. (2025). IGF-1 signaling pathway activation promotes axonal regeneration and repair: A mechanism study on catalpol-induced functional recovery after ischemic stroke. Journal of ethnopharmacology, 348, 119808. https://doi.org/10.1016/j.jep.2025.119808 
  • Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology and Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
  • Tomas, F. M. (2001). Insulin-like growth factor-I (IGF-I) analogue, LR(3)IGF-I, ameliorates the loss of body weight but not of skeletal muscle during food restriction. Growth Hormone & IGF Research, 11(2), 92–103. https://doi.org/10.1054/ghir.2000.0194
    Complete Peptides+ 1

Written by Amanda Bates, RN and medically reviewed by Dr. Stephen Matta